Thus, the mechanistic role of HAPSTR1 in OV is reported for the first time, and our study also has provided new insights into the mechanisms by which LRPPRC influences the malignant progression of ovarian cancer, highlighting LRPPRC as a significant therapeutic target in the context of ovarian cancer treatment. This evidence concerns the gene HAPSTR1 and ovarian carcinoma.